Forest Lexapro launch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest will launch its antidepressant Lexapro (escitalopram) Sept. 5 at a slight discount to parent drug Celexa. FDA cleared the single-isomer follow on to citalopram Aug. 14. Labeling reports greater potency than Celexa in terms of inhibition of 5-HT reuptake, and Forest says the 10 mg recommended starting dose was shown to be comparable to Celexa 40 mg. The firm is highlighting early relief with Lexapro, although labeling does not include onset of action data. The Lexapro NDA was submitted March 23, 2001, and deemed "approvable" Jan. 25. Forest will stop sampling and promotion of Celexa, which loses exclusivity in January 2004 after a six-month pediatric extensio
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.